Background: Hyperuricemia is increasingly recognized as an independent risk factor for hypertension and related cardiovascular outcomes. However, little is known about its burden among hypertensive populations in Tanzania. Methods: We conducted a cross-sectional study of 311 adults with hypertension attending the outpatient clinic at Bugando Medical Centre, Mwanza. Data on sociodemographic, clinical, and laboratory characteristics were collected using a structured questionnaire. Serum uric acid, lipid profile, and renal function were measured. Hyperuricemia was defined as serum uric acid >450 μmol/L in men and >360 μmol/L in women. Logistic regression was used to identify associated factors. Results: The prevalence of hyperuricemia was 59.8% (186/311). In multivariable analysis, hyperuricemia was independently associated with elevated body mass index (OR 2.96, 95% CI 1.40–6.25), systolic blood pressure ≥140 mmHg (OR 1.93, 95% CI 1.18–3.16), dyslipidemia (OR 1.71, 95% CI 1.03–2.85), and reduced glomerular filtration rate (OR 2.77, 95% CI 1.21–6.30). Use of calcium channel blockers was protective (OR 0.56, 95% CI 0.34–0.90). Conclusion: Hyperuricemia is highly prevalent among hypertensive patients in Tanzania and is associated with obesity, dyslipidemia, uncontrolled systolic blood pressure, and impaired renal function. Routine screening and consideration of calcium channel blockers in hypertensive management may help reduce cardiovascular risk.
Background: Colchicine is widely used for the treatment of acute gout flares due to its anti-inflammatory properties. Beyond this traditional role, colchicine has been implicated in modulating various physiological systems, including glucose metabolism. Notably, it exhibits a biphasic effect on blood glucose levels causing hypoglycemia at lower doses and hyperglycemia at higher doses. However, its impact on glycemic control in diabetic patients undergoing dialysis remains poorly characterized. Case Reports: We report two cases from the Dialysis Unit at Kilimanjaro Christian Medical Centre (KCMC) in northern Tanzania involving two Black African diabetic males aged 66 and 62 years with end-stage renal disease (ESRD) on maintenance hemodialysis. Both patients experienced a notable and reproducible decline in blood glucose levels following colchicine administration for gout flares. The hypoglycemia occurred in the absence of other identifiable precipitating factors and resolved upon withholding colchicine. Discussion: These observations raise important questions regarding the potential glucose-lowering effects of colchicine in dialysis dependent diabetic patients. The exact mechanism remains unclear but may involve colchicine’s influence on insulin sensitivity, hepatic glucose production, or inflammatory pathways that indirectly affect glucose metabolism. Given the already high risk of hypoglycemia in ESRD patients, these findings warrant careful consideration and further investigation. Conclusion: Colchicine may have an under recognized hypoglycemic effect in diabetic patients undergoing dialysis. Clinicians should be alert to this potential interaction, particularly in patients with poor glycemic reserve. Further research is needed to elucidate the mechanisms involved and assess whether colchicine could be repurposed as an adjunctive agent for glycemic control in selected ESRD populations.
Background: Diabetic peripheral neuropathy (DPN) is a common and disabling complication of Type 2 diabetes mellitus (T2DM). Emerging evidence suggests that elevated serum uric acid (SUA) may associate with microvascular complications; however, data from sub‐Saharan Africa remain limited. We examined the association between hyperuricemia and DPN among adults with T2DM in northern Tanzania. Methods: We conducted a hospital‐based cross‐sectional analytical study at a tertiary diabetes clinic from November 2024 to April 2025. Adults aged ≥ 18 years with established T2DM were consecutively recruited. DPN was assessed using the Toronto Clinical Scoring System (TCSS), with DPN defined as TCSS ≥ 6. Fasting SUA was classified as elevated at ≥ 340 μ mol/L in women and ≥ 420 μ mol/L in men. Multivariable logistic regression estimated adjusted odds ratios (aORs). Receiver operating characteristic (ROC) analysis assessed discriminatory performance. Results: Of 321 clinic attendees, 220 participants met eligibility criteria and were analyzed (mean age < 65 years: 69.1%; male: 53.2%). DPN prevalence was 51.8% (114/220). Elevated SUA was present in 52.7% and was strongly associated with DPN (aOR 5.89, 95% CI 3.01–11.51, p < 0.001). Diabetes duration ≥ 5 years (aOR 3.81, p = 0.016), overweight status (aOR 2.18, p = 0.034), elevated fasting glucose (aOR 2.20, p = 0.022), and low HDL (aOR 2.10, p = 0.040) were independently associated with DPN. Elevated total cholesterol was inversely associated (aOR 0.36, p = 0.003). SUA demonstrated moderate discrimination for DPN (AUC 0.773). Conclusions: Hyperuricemia was independently associated with prevalent DPN in this Tanzanian study. SUA may represent a clinically accessible marker for neuropathy risk stratification in resource‐limited settings.
Background Tramadol is a widely used analgesic for moderate to severe pain due to its dual mechanism of µ-opioid receptor agonism and monoaminergic reuptake inhibition. While generally perceived as safe, it has been increasingly associated with neurotoxic side effects, particularly seizures. These adverse effects are commonly reported in patients with epilepsy, polypharmacy, or organ dysfunction. However, seizure events in elderly individuals without known risk factors are rare and underreported. Case Presentation: We describe a 72-year-old woman with no prior medical history who developed a generalized tonic-clonic seizure after administration of tramadol for an upper respiratory tract infection. She had received three therapeutic doses of tramadol. Her laboratory investigations and neuroimaging were unremarkable. Following withdrawal of the drug, the patient made a full recovery with no further seizure activity. Discussion Elderly patients are particularly vulnerable to adverse drug reactions due to altered pharmacokinetics and pharmacodynamics associated with aging. This case highlights the potential for tramadol to induce seizures even in the absence of predisposing comorbidities or drug interactions. Clinicians should be vigilant when prescribing tramadol to older individuals and should consider alternatives for pain control. Conclusion Tramadol should be prescribed with caution in elderly populations, regardless of apparent baseline health. Clinician awareness of tramadol’s seizure risk even at therapeutic doses is essential to patient safety.